Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H9I3N2O4 |
Molecular Weight | 613.9136 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I
InChI
InChIKey=YVPYQUNUQOZFHG-UHFFFAOYSA-N
InChI=1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20)
DescriptionSources: http://www.drugbank.ca/drugs/DB00271Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00271
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety. A commonly used x-ray contrast medium. Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues.
CNS Activity
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=3198373
Curator's Comment: Diatrizoic acid was discovered in 1953 simultaneously and independently by Schering AG in Berlin and by Sterling-Winthrop in the USA.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Cystografin Approved UseRetrograde cystourethrography Launch Date1955 |
|||
Diagnostic | Gastrografin Approved UseGastrografin (DIATRIZOIC ACID) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). Launch Date1958 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.6 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
102 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
An approach to the performance of contrast studies in contrast material-reactive persons. | 1975 Aug |
|
Reversibility of experimental acute renal failure in rats: assessment with USPIO-enhanced MR imaging. | 2000 Aug |
|
Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model. | 2000 Sep |
|
Dose reduction in evacuation proctography. | 2001 |
|
Spontaneous pneumomediastinum. | 2001 Apr |
|
Temporary pancreatic duct occlusion by ethibloc: cause of microcirculatory shutdown, acute inflammation, and pancreas necrosis. | 2001 Apr |
|
Shielding effects of metallic encapsulations and radiographic contrast agents for catheter-based intravascular brachytherapy. | 2001 Apr-Jun |
|
The use of dilute Calogen as a fat density oral contrast medium in upper abdominal computed tomography, compared with the use of water and positive oral contrast media. | 2001 Aug |
|
Flow-directed microcatheters for cerebral embolizations using Ethibloc--an in vitro study. | 2001 Dec |
|
The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency. | 2001 Feb 23 |
|
Review of studies establishing the aging male spontaneously hypertensive rat as a detector and quantifier of the kidney toxicity of radiocontrast media and other chemicals. | 2001 Jan |
|
[Evaluation of aqueous compartments of the body by integral bioimpedance spectrometry in x-ray surgical interventions in children]. | 2001 Jan-Feb |
|
Mixed-type hiatal hernia mimicking pulmonary cystic lesion diagnosed by oral urografin in ED. | 2001 Jul |
|
CT colonography without cathartic preparation: feasibility study. | 2001 Jun |
|
Harmonic scalpel in laparoscopic colorectal surgery. | 2001 Mar |
|
Contrast medium precipitation in the stomach between contiguous plain and contrast CT scans. | 2001 May-Jun |
|
Retrospective study on the effects of lipiodolization before a potentially curative hepatectomy for colorectal liver metastases: long-term results of a pilot study. | 2001 May-Jun |
|
Rapid diagnosis of sigmoid volvulus with water soluble urografin in emergency service. | 2001 Nov |
|
Appendiceal disease in women with endometriosis and right lower quadrant pain. | 2001 Nov |
|
Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. | 2001 Nov |
|
Pseudomembranous colitis without diarrhea presenting clinically as acute intestinal pseudo-obstruction. | 2001 Sep |
|
Ionic radiocontrast media disrupt intercellular contacts via an extracellular calcium-independent mechanism. | 2002 |
|
Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. | 2002 Apr |
|
Diagnosis and management of enterovesical fistulas in patients with Crohn's disease. | 2002 Aug |
|
Electrocardiographic effects of diagnostic imaging agents. | 2002 Aug |
|
Thumbprinting due to ischemic colitis in a patient on oral anticoagulation. | 2002 Aug-Sep |
|
Use of near-infrared reflection spectroscopy to study the effects of X-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors. | 2002 Dec |
|
Rectal washout with cytotoxic solution can be extended to the whole colon. | 2002 Dec |
|
Evidence for involvement of mast cell degranulation and subsequent stimulation of histamine H1 and H2 receptors in radiographic contrast media-increased vascular permeability in rats. | 2002 Dec |
|
The utility of contrast studies and drains in the management of patients after Roux-en-Y gastric bypass. | 2002 Feb |
|
Effects of intrathecal injection of diatrizoate on dopamine receptors. | 2002 Jul |
|
Contrast radiography and intestinal obstruction. | 2002 Jul |
|
Therapeutic value of gastrografin in adhesive small bowel obstruction after unsuccessful conservative treatment: a prospective randomized trial. | 2002 Jul |
|
Laparoscopic repair for perforated peptic ulcer: a randomized controlled trial. | 2002 Mar |
|
Do clinically relevant circulating concentrations of radiographic contrast agents inhibit platelet-dependent arterial thrombosis? | 2002 Mar 1 |
|
A case of gastric duplication evaluated by gastric emptying scintigraphy. | 2002 May |
|
Long-term survival of patients with stage IV hypopharyngeal cancer: impact of fundus rotation gastroplasty. | 2002 May |
|
New strategies in nonoperative management of meconium ileus. | 2002 May |
|
Jejunum free flap in hypopharynx reconstruction: case series. | 2002 May 10 |
|
The role of theophylline in contrast-induced nephropathy: a case-control study. | 2002 Nov |
|
The value of contrast radiology for postoperative adhesive small bowel obstruction. | 2002 Nov-Dec |
|
Venous port salvage utilizing low dose tPA. | 2002 Nov-Dec |
|
Renal chemoembolization with mitomycin c/Ethibloc: pharmacokinetics and efficacy in an animal model. | 2002 Sep |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: For radiographic examination of segments of the gastrointestinal tract (Gastrografin) oral administration: adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For Enemas or Enterostomy Instillations: should be diluted when it is used for enemas and enterostomy instillations. When used as an enema, the suggested dilution for adults is 240 mL (88 g iodine) in 1,000 mL of tap water. http://www.drugs.com/pro/gastrografin.html
;
The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C390
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
||
|
NDF-RT |
N0000180185
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
||
|
WHO-VATC |
QV08AA01
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
||
|
WHO-ATC |
V08AA01
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
||
|
NDF-RT |
N0000010258
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00271
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
m4263
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000091574
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
59733
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
C016826
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
C47483
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
DTXSID0044521
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
Diatrizoate
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
4042
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
1184005
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
5UVC90J1LK
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
DIATRIZOIC ACID
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless. Solubility: Very slightly soluble in water and ethanol (~750 g/l) TS; soluble in dimethylformamide R; sparingly soluble in methanol R; practically insoluble in ether R; dissolves in solutions of alkali hydroxides. Category: Used in the preparation of meglumine amidotrizoate as a radiocontrast medium. Storage: Amidotrizoic acid should be kept in a well-closed container, protected from light. Labelling: The designation on the container of amidotrizoic acid should state whether the substance is the dihydrate or the anhydrous form. Requirement: Amidotrizoic acid contains not less than 98.0% and not more than the equivalent of 102.0% of C11H9I3N2O4, calculated with reference to the dried substance. | ||
|
SUB00443MIG
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
5UVC90J1LK
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
117-96-4
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
262168
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
851
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
1546223
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
D003973
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
DIATRIZOIC ACID
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
2140
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201220
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
204-223-6
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY | |||
|
3319
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
ALTERNATIVE | |||
|
53691
Created by
admin on Fri Dec 15 15:08:22 GMT 2023 , Edited by admin on Fri Dec 15 15:08:22 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)